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1. Introduction 
The concept of targeted drug delivery implies selective accumulation of the drug in the 
tissue affected by the pathological process after systemic administration of the drug and its 
carrier with minimal effect of the former on the intact organs and tissues (Lammers et al., 
2010). The idea of targeted delivery has been first suggested by Paul Erhlich in 1906 when he 
introduced the concept of «magic bullet» which is directed against target cells only without 
any damage to healthy tissue (Erhlich, 1906). In the current medical practice, most of the 
drugs are administered orally or parenterally, resulting in natural biodistribution and 
systemic effect on the organism. This type of distribution is justified for the drugs which act 
on the systemic mechanisms of disease development and progression. At the same time, in 
case of focal pathological processes such as tumor growth, inflammation and ischemia it 
may be more clinically attractive to ensure the local rise in the drug concentration within the 
pathological area thus avoiding the putative side effects on neighboring tissues. This point 
can be illustrated by several examples. It is known that the administration of antitumor drug 
doxorubicin is associated with severe cardiomyopathy, suppression of myelo- and 
megakaryopoiesis, nausea, vomiting, and development of alopecia (Carvalho et al., 2009). 
Encapsulation of doxorubicin into liposomes resulted in dramatic reduction of these dose-
limiting side effects (Leonard et al., 2009). The implementation of site-specific drug delivery 
may also benefit female patients receiving estrogens for treatment of osteoporosis. Along 
with desirable effect on the bone, estrogens may cause some unwanted effects, especially 
increased risk of uterine bleeding and development of endometrial cancer (Romer, 2006). 
One might suggest that bone-targeted delivery of estrogens will decrease the probability of 
these side effects. The application of nano-sized particles for drug transport may offer a new 
means of delivering drugs selectively into the affected tissue. 
Typical nanoparticulate carrier for targeted drug delivery comprises several functional 
elements. The major part of the carrier is drug-loaded nanoparticle. An important step in 
nanocarrier fabrication is the functionalization of its surface which implies binding of the 
targeting ligands to the nanoparticle surface. Targeting ligand ensures specific interaction of 
the nanoparticle with the complementary molecules on the surface membrane of the target 
cell. In order to facilitate the process of functionalization and prevent rapid clearance of 
nanoparticles by the reticulo-endothelial system, the surface of the nanoparticle is often 
covered with biocompatible coating such as polyethylene glycol. The nanoparticles can be 
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additionally labeled with radioactive isotopes or fluorescent dyes which allows 
visualization of their accumulation in the damaged tissue. Successful targeted drug delivery 
with use of nanoparticulate carriers can bring solutions to several serious problems. In 
particular, it may result in reduced toxicity, increased solubility and stability of the drugs. 
To date, the research on targeted drug delivery has been mostly concentrated on the 
development of tumor-targeted nanomedicines (Ali et al., 2011). It might be hypothesized 
that targeted drug delivery strategy approved in oncology can be applied in other clinical 
fields, now not for destruction but for the sake of salvage of reversibly injured cells, in 
particular of those destined otherwise to die within the area of myocardial ischemia-
reperfusion. One reasonable approach to the problem may be targeted intramyocardial 
delivery of the agents (i.e., certain angiogenic growth factors, erythropoietin, ATP-sensitive 
potassium channel openers, etc.), either covalently and/or non-covalently bound to the 
nanoparticulate carriers. Thus, the purpose of this chapter is to provide an account of 
acquired knowledge on nanoparticle-based targeted drug delivery with particular emphasis 
on heart targeting. Besides, the original experimental data on the fabrication of silica 
nanoparticles which can be used as prototype carriers for cardioprotective drugs are 
presented. We also present the data on silica nanoparticle biodistribution, biodegradation, 
and acute toxicity. Finally, the preliminary evidence for enhanced infarct size limitation with 
use of silica nanoparticle-bound adenosine is provided. 
2. Major types of nanocarriers for targeted drug delivery 
The various types of nano-sized particles can be utilized for transport of drugs into the 
diseased tissues. Liposomes, drug-polymer conjugates, polymeric micelles, dendrimers, 
nanoshells, and nucleic acid-based carriers can all be used as nanocarriers for drugs (Wang 
et al., 2008). Among them, drug-polymer conjugates and liposomes are currently most 
commonly used for drug delivery in the clinical settings and collectively amount to at least 
80% of all nanopharmaceuticals available on the market. The choice of the material for 
nanocarrier fabrication mainly depends on the chemical structure of the drug to be 
transported, characteristics of the target tissue and the route of nanocarrier administration 
into the organism (Ganta et al., 2008). It is generally accepted that the properties of ideal 
nanocarrier should include biocompatibility, biodegradability, and evasion of rapid uptake 
by the macrophages. 
2.1 Liposomes 
Liposomes are spherical membrane structures that consist of a phospholipid bilayer which 
can entrap aqueous solutions. In the past decade, considerable information has been 
accumulated on the therapeutic applications of liposomes (Fenske & Cullis, 2008). By now, 
there are 9 liposomal drugs approved for clinical use. Liposomal doxorubicin and 
daunomycin are successfully used for treatment of cancer while liposomal amphotericin 
remains to be a cornerstone for the treatment of some fungal infections. 
2.2 Polymer-drug conjugates 
Peptides and the drugs with low molecular weight are often characterized by the short half-
life in the circulation thus requiring repeated administration and, furthermore, can exhibit 
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non-specific adverse effect on organs and tissues. Binding of the drugs with polymer 
nanocarriers may reduce these negative effects. Despite the fact that a great number of 
diverse polymers have been initially considered for drug delivery, the very few of them 
have been finally approved for clinical applications. Polyethylene glycol is the most 
universal polymer drug carrier. It has been introduced in the clinical practice in the early 90s 
and has rapidly become popular as drug vehicle because of its capability to increase the 
stability of drugs in the plasma, improve solubility of hydrophobic drugs and reduce their 
immunogenicity. Apart from polyethylene glycol, gamma-polyglutamic acid, N-(2-
hydroxypropyl) methacrylamide and certain polysaccharides with linear structure are 
currently viewed as promising polymeric drug carriers (Sanchis et al., 2010). Tissue-
recognition ligands engrafted on the polyethylene glycol chain conjugated with the drug 
may facilitate targeted delivery of the entire complex into the tissue of interest. 
2.3 Dendrimers 
Dendrimers represent three-dimensional highly branched polymeric macromolecules with 
the diameter varying from 2.5 to 10 nm. Dendrimers can be synthesized from both synthetic 
and natural monomers, e. g. amino acids, monosaccharides and nucleotides. High surface 
area, narrow range of polydispersity and abundance of functional groups on the outer shell 
of dendrimers make them an attractive tool for targeted drug delivery (for review, see 
Cheng et al., 2008). Two classes of dendrimers are most commonly used for biomedical 
applications – polyamidoamines and polypropyleneimines. Although polycationic 
macromolecules such as dendrimers were shown to be moderately toxic for living cells, the 
attachment of polyethylene glycol (PEGylation) to the dendrimer can overcome this 
limitation. The methods of drug binding to the surface of dendrimer include covalent 
conjugation and electrostatic adsorption. Besides, low molecular weight drugs can be placed 
into the cavities within the dendrimer molecules being temporarily immobilized there with 
hydrophobic forces, hydrogen and covalent bonds. 
2.4 Polymeric nanoparticles  
Biodegradable polymeric nanoparticles were extensively studied as drug carriers. This type 
of nanocarriers is usually synthesized by means of self-assembly of copolymers consisting of 
two or more blocks with different hydrophobicity. In the aqueous environment, these 
copolymers spontaneously form micellar structures with hydrophilic shell and hydrophobic 
core (Torchilin, 2007). Hydrophobic core may serve as an ideal container for water-insoluble 
drugs while the hydrophilic shell can be additionally modified for attachment of water-
soluble drugs. Polymeric nanoparticles can in principle transport not only low molecular 
weight hydrophilic and hydrophobic drugs but also the macromolecules such as proteins 
and nucleic acids (Perez et al., 2001). The kinetics of the release of nanoparticle-bound drug 
depends on the duration of nanoparticles residence in the organism and characteristics of 
their microenvironment. Polylactide, polyglycolide and poly(ε–caprolactone) as well as their 
diblock copolymers with polyethylene glycol at different molar ratios are most commonly 
used for fabrication of biodegradable nanoparticles. In general, biodegradable polymeric 
nanoparticles maintain therapeutic drug concentration in the tissue of interest for a longer 
period of time than other nanocarriers. This feature makes them suitable platforms for 
transport of highly toxic, water insoluble and unstable drugs. 
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2.5 Metallic nanoshells  
Metallic nanoshells typically consist of dielectric core and thin metallic shell which increases 
their biocompatibility and optical absorption. The resonance frequency at which the 
nanoshells demonstrate maximal absorption of energy and its minimal dissipation strongly 
depends on the ratio between the diameter of the core and the thickness of the metallic layer 
on the surface of the particle. Gold nanoshells heated with use of near-infrared light were 
successfully used for photothermal destruction of tumors in vivo (Hirsch et al., 2003). 
Similarly, thermosensitive polymer hydrogels and optically active nanoshells may be used 
for targeted delivery of drugs. For instance, Arias et al. (2006) developed nanoshells 
consisting of magnetic core (carbonyl iron) and biodegradable coating 
(polybutylcyanacrylate) designed for controlled release of 5–fluorouracil in the tumor tissue. 
2.6 Nucleic acid-based nanoparticles 
RNA and DNA can also play a role of macromolecular carriers for delivery of the drugs. For 
fabrication of nucleic acid nanoparticles, modified chains of RNA or DNA with non-linear 
shape are utilized. One of the studies on this topic provided the description of 100 nm 
multifunctional complex on the basis of DNA designed for consecutive targeted delivery of 
the drug, visualization of the pathologic focus and gene therapy (Li et al., 2004). The effects 
of RNA nanoparticles (25-40 nm) containing inactive RNA within the core, RNA aptamers 
as targeting ligands and small interfering RNA for inhibition of tumor cells were 
investigated in another recent study (Khaled et al., 2005). 
3. Passive and active targeting 
Two main strategies currently utilized for site-specific drug delivery are passive and active 
tissue targeting. In passive targeting, nanoparticles of specific size and charge are 
nonspecifically accumulated within the affected tissue because of the special characteristics 
of its vascular bed. Good example of passive targeting is selective accumulation of 
PEGylated nanoparticles within the tumor tissue after their intravenous administration. This 
phenomenon is explained by the increased permeability of the tumor microvessels which, in 
turn, is due to defective endothelial lining and local fenestrations of basement membrane. 
These observations were first made by Matsumura & Maeda (1986) in the murine solid 
tumors and are usually referred to as enhanced permeability and retention phenomenon. 
Due to the enhanced permeability and retention phenomenon, systemic administration of 
polymer-drug conjugates results in 10-100-fold higher concentration of the drug in the 
tumor tissue than after administration of aqueous solution of the drug. Enhanced 
permeability and retention effect has been observed not only in tumors but also in chronic 
inflammation and infection. Furthermore, it is well established that nanoparticles without 
polymer coating are rapidly eliminated from the circulation because of the uptake by the 
reticulo-endothelial system elements. This fact provides a rationale for passive targeting of 
liver and spleen in chronic inflammatory diseases associated with prolonged persistence of 
pathogens within the macrophages (e.g.candidiasis , listeriosis, leishmaniasis, brucellosis, 
etc.). Stimuli-responsive nanoparticles have recently emerged as another feasible approach 
to passive targeting (Ganta et al., 2008).  
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It has been shown that nanoparticles diameter and charge can have a significant impact on 
their ability to accumulate in the damaged tissue. For instance, van Vlerken et al. (2007) 
suppose that the most intensive and prolonged accumulation within the tumor is typical for 
positively charged nanoparticles with diameter of less than 200 nm.  
Active targeting employs nanoparticles with specific targeting ligands which selectively 
bind to biomarkers on target cells. These biomarkers include integrins ǂVǃ5 and ǂVǃ3 which 
are expressed on the tumor cells and endothelial cells of the tumor vessels.  It is documented 
that integrins ǂVǃ5 and ǂVǃ3 specifically interact with arginine-glysine-aspartic acid (RGD) 
tripeptide sequence. It follows, therefore, that the attachment of RGD peptide to the surface 
of antitumor drug-loaded nanoparticles may result in their targeted delivery to the tumor 
tissue. Other variants of targeting ligands are considered in the following section. 
4. Tissue-recognition ligands 
Monoclonal antibodies and their fragments, aptamers, peptides and low molecular weight 
compounds may function as tissue-recognition ligands. Considerable efforts have been 
directed towards developing targeted drug delivery systems with use of monoclonal 
antibodies. Synthetic monoclonal antibodies are most commonly used for this purpose. For 
example, the conjugation of fluorescent polystyrene nanoparticles with monoclonal 
antibodies against platelet endothelial cell adhesion molecule-1 resulted in efficient 
internalization of the entire complex into the endothelial cells (Garnacho et al., 2008). It was 
shown in this study that the fate of the nanoparticle (presence of endocytosis, intracellular 
trafficking, and fusion of vesicles with lysosomes) was dependent on the type of the 
monoclonal antibody epitope against platelet endothelial cell adhesion molecule-1. On the 
basis of these data, one might suggest that the drugs can be delivered not only in the 
affected cells but also in the specific intracellular compartments. 
The use of native monoclonal antibodies for tissue targeting is limited by their considerable 
immunogenicity. In this connection, the development of chimeric and humanized 
monoclonal antibodies is of importance. The use of monoclonal antibodies as targeting 
ligands has several other disadvantages such as high cost of monoclonal antibodies 
fabrication and significant variability of their specificity from batch to batch. Antigen 
recognition fragments such as Fab fragments, single-chain variable fragments, minibodies, 
diabodies, and nanobodies may become an alternative to antibodies. Nanobodies are the 
smallest antibody-derived structures which are produced from the variable domain of the 
heavy chain of single-domain immunoglobulins and retain the ability to recognize specific 
antigen. Nanobodies seem to be optimal tissue recognition ligands since they have small 
size and low immunogenicity. Qiu et al. (2007) produced low-molecular weight antibody 
mimetics by virtue of fusion between two complementarily-determining regions of the 
prototype antibodies. Obtained mimetics with molecular weight of 3 kDa were 
characterized by the better distribution pattern than corresponding antibodies, suggesting 
that these mimetics may be used as highly specific targeting ligands. 
Aptamers are small nucleic acid molecules which may function as specific receptors for low-
molecular weight organic substances. The selection of aptamers specific for certain 
molecular target is a laborious and complicated procedure consisting of several stages. One 
of the major stages is the enrichment of combinatorial oligonucleotide libraries including up 
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to 1015 random sequences resulting in the identification of aptamers specifically interacting 
with target molecule. The advantages of aptamers include low molecular weight (around 15 
kDa) and low immunogenicity leading to improved pattern of tissue distribution (Zhou & 
Rossi, 2011). It is worth noting that the technology of aptamer synthesis can be easily scaled 
to industrial production, as opposed to synthesis of monoclonal antibodies. It has been 
shown that RNA aptamers for recognition of vascular endothelial growth factor can cause 
regression of tumor microvessels and demonstrate high stability in plasma of the monkey 
(Ruckman et al., 1998). Anti-vascular endothelial growth factor aptamer pegaptanib has 
been approved by the American Food and Drug Administration in 2004 for clinical use in 
the patients with age-related macular degeneration. This fact underscores rapid 
advancement of aptamers from the bench to clinical applications. 
In the last years, with the advent of combinatorial peptide libraries, the peptide targeting 
ligands are becoming more and more widespread. The peptides can bind to target molecule 
with very high specificity and affinity. For instance, cyclic peptide cilengitide, an integrin-
targeting RGD peptide, is currently being tested in the phase I/II clinical trial for therapy of 
recurrent and/or metastatic squamous cell cancer of the head and neck (Vermorken et al., 
2011).  
Low-molecular weight compounds may also serve as efficient tissue-recognition ligands 
because of their low cost and negligible immunogenicity. One of the most intensively 
studied molecules within this group is folic acid. Folate is especially helpful for tumor 
targeting since tumor cells are over-expressing folate receptor on their surface. Folic acid has 
been used for tumor-targeted delivery of cytostatics immobilized on different types of 
nanoparticulate carriers (e. g., polymeric nanoparticles, liposomes, dendrimers, etc.). 
Various methods of binding targeting ligand with the nanoparticle surface have been 
suggested, which can be generally divided into covalent and non-covalent techniques. 
Covalent binding has been suggested more than 25 years ago for immobilization of proteins 
on the surface of liposomes. Protein conjugation with the nanoparticle is usually mediated 
through the bifunctional polyethylene glycol which contains hydrophobic anchor for 
fixation in the liposomal coating and molecular spacer with amino or sulfhydryl moieties for 
drug binding. Specific interaction between protein A and Fc-fragments of monoclonal 
antibodies as well as the biotinylation of the nanoparticles and their subsequent conjugation 
with ligand-streptavidin complex can both be used for non-covalent binding of nanoparticle 
with targeting ligand. 
5. Heart targeting with nanoparticulate carriers 
Much of the work on targeted drug delivery has focused on cancer treatment. The reasons 
for this include high morbidity and mortality due to cancer as well as focal tumor growth 
associated with severe alterations in tumor molecular phenotype, thus making possible the 
design of highly selective targeting ligands. However, it can be hypothesized that the 
concepts of passive and active targeted drug delivery can be applied efficiently to any type 
of focal pathological process including ischemia-reperfusion and inflammation. Ischemic 
heart disease is generally thought to be a major cause of morbidity and mortality 
worldwide. It follows, therefore, that prevention and/or alleviation of myocardial ischemia-
www.intechopen.com
 
Cardiac Protection with Targeted Drug Delivery to Ischemic-Reperfused Myocardium 259 
reperfusion injury remains to be among the most important goals of the medical care. One 
solution to the problem might be direct delivery of cardioprotective drugs into the ischemic 
myocardium.  
At present, there is some, albeit limited, published evidence that the ischemic heart can be 
actively and passively targeted with drug-loaded liposomes. In particular, anti-myosin 
monoclonal antibody-doped liposomes containing ATP were administered to the isolated 
rat heart prior to global ischemia-reperfusion (Verma et al., 2006), which was associated 
with better postischemic contractile recovery. Intracoronary infusion of non-targeted ATP-
loaded liposomes before regional ischemia-reperfusion resulted in significant reduction in 
infarct size as compared to controls in rabbit model (Verma et al., 2005). One possible 
limitation of these studies is that drug-loaded nanocarriers were administered prior to 
ischemia instead of administering at the end of ischemia or at the early stage of reperfusion. 
It seems justified that myocardial nanoparticle accumulation is most intensive at the time of 
reperfusion. Therefore, one can also expect to get the best result as to the extent of 
myocardial protection when infusing nanoparticle-loaded drug at this time. There are 
several lines of evidence in support of this notion. First, myocardial cell injury associated 
with exposure/expression of injury markers required for active targeting becomes more 
pronounced after reperfusion. Second, myocardial reperfusion initiates the inflammatory 
response associated with increased microvascular permeability, the latter being a major 
prerequisite of passive targeting. Third, reperfusion is accompanied by reactive hyperemia 
which may contribute to better delivery of nanocarriers to the area of interest. Fourth, early 
stage of reperfusion itself strongly contributes to the formation of irreversible myocardial 
injury (Yellon & Hausenloy, 2007). Hence, the release of nanoparticle payload at this narrow 
time interval may prevent or block some of the mechanisms of lethal reperfusion injury. 
Thus, in order to optimize the pharmacokinetic profile of the heart-targeted drug delivery 
system, it should be administered at the final stage of ischemia or at the very beginning of 
reperfusion. In conclusion, the timing of nanoparticle-loaded cardioprotective drug 
administration is crucial for successful heart targeting. 
In the study of Scott et al. (2009), the vascular endothelial growth factor-loaded liposomes 
functionalized with monoclonal antibodies against P-selectin were administered 
intravenously to the rats after permanent coronary artery ligation. The authors showed 
increased density of capillaries within the infarct area 4 weeks after infarction and better 
post-infarct left ventricular function. Despite positive findings, it is difficult to extrapolate 
the results of this study to the current clinical practice since it was performed with use of 
permanent ischemia model without reperfusion. At the same time, current gold standard for 
treatment of acute coronary syndrome is prompt myocardial revascularization. Besides, the 
benefits of applied treatment regimen might be explained rather by the improved 
neovascularizarion of peri-infarct area, and not by the direct prevention of cardiac myocyte 
death within the ischemic area.    
Important results were obtained in a landmark study by Takahama et al. (2009) who used 
liposomal adenosine for treatment of myocardial ischemia-reperfusion in rats. Adenosine-
loaded liposomes were infused intravenously for 10 minutes starting 5 minutes prior to 
myocardial reperfusion. Selective accumulation of liposomes within the ischemic-reperfused 
area was verified with electron microscopy, optical fluorescence, and radionuclide imaging. 
Besides, liposomal adenosine administration was associated with more significant infarct 
size limitation and less severe arterial hypotension as compared to free adenosine treatment. 
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The research of our group working at the Institute of Experimental Medicine, V.A. Almazov 
Federal Heart, Blood and Endocrinology Centre is focused on the development of both 
active and passive techniques of heart targeting. We hypothesized that local accumulation of 
drug-loaded nanoparticles within the ischemic area of the heart may be achieved by 
selective binding of the annexin V to the nanoparticle surface (Fig. 1).  
 
Fig. 1. Proposed algorithm of active targeted drug delivery into the ischemic cardiac muscle 
Annexin V is a naturally expressed protein that binds to phosphatidylserine in a calcium-
dependent fashion. Phosphatidylserine is normally localized on the inner surface of the 
plasmalemma, but it is translocated on the exterior cell surface when sublethal cell injury 
occurs (Vance & Steenbergen, 2005). Annexin V is widely used as one of the marker proteins 
for cell injury and apoptotic cell death in vitro. Besides, the intravenous administration of 
annexin V conjugated with fluorescent probe to the dogs subjected to 1 hour regional 
ischemia and 1 hour reperfusion resulted in bright fluorescence of ischemic area indicative 
of site-specific conjugate accumulation (Ohnishi et al., 2006). Specific interaction of the 
nanoparticle-anchored annexin V with phosphatidylserine would potentially result in the 
binding of nanoparticles to the cardiomyocyte membrane with their subsequent 
accumulation in the area of interest. 
Apart from active heart targeting with use of annexin V as a tissue-recognition ligand, we 
also feel that ischemic-reperfused myocardium may offer an advantage of passive targeting. 
The basic idea is that the nanoparticulate carriers, if administered in proper time (see above), 
can be retained within the ischemic-reperfused area of the heart owing to local 
inflammatory response and severely increased microvascular permeability. In this regard, 
the functional characteristics of myocardial microvessels are more or less similar to those of 
the tumor. Therefore, it seems not unlikely that drug-loaded nanoparticles can tend to 
accumulate within the ischemic-reperfused area of the heart just because of the raised 
permeability of myocardial capillaries. 
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5.1 Fabrication, characterization, and surface modification of silica nanoparticles  
Among inorganic drug carriers, nanodisperse silica, titania, zirconia, and iron oxide as well 
as fullerenes and carbon nanotubes have been considered to be the most promising. In our 
studies, the prototype carriers for antiischemic drugs are suggested to be nanodispersed 
silica particles. It has been shown before that silica nanomaterials are characterized by fairly 
good biocompatibility and biodegradability (Slowing et al., 2008). Chemical modification of 
silica nanoparticle surface can be performed with use of two different synthetic approaches, 
namely, immobilization and chemical assembly. In immobilization strategy, the modifier is 
attached to the carrier surface with use of a single-stage reaction. Chemical assembly 
represents another approach toward synthesis of engrafted surface compounds that has 
recently emerged as a promising alternative to immobilization strategy. Chemical assembly 
is based on multistage synthesis of engrafted chemical compounds on the surface of solid 
phase particles which play a role of matrices. The major advantage of chemical assembly in 
comparison to immobilization is the larger diversity of functional groups that can be applied 
to the matrix surface. 
Taking into account the above considerations, we suppose that nanodisperse silica of the 
Aerosil type may be a perspective drug carrier for biomedical applications. In our studies, 
the standard pyrogenic highly dispersed silica (Aerosil A380 mark obtained from Vekton, 
Russia) was used throughout experiments. Surface area of silica nanoparticles was 
determined with use of Brunauer-Emmett-Teller (BET) method and averaged from 170 to 
380 m2/g (Galagudza et al., 2010). The mean particle diameter varied from 6 to 13 nm. The 
technique of silica nanoparticle functionalization included three sequential steps: 
modification of silica nanoparticles with (3-aminopropyl)triethoxysilane, hydrolysis of 
unreacted alkoxysilane groups, and binding of fluorescein. Chemosorption of (3-
aminopropyl)triethoxysilane was performed from the gaseous phase with use of dried 
nitrogen as a carrier gas. The synthesis was done in the vertical quartz flow reactor at 220°C 
during 2 hours. Hydrolysis of the unreacted alkoxysilane groups was achieved with water 
vapor at 150°C during 1 hour. The covalent binding of fluorescein to the aminated silica was 
done using carbodiimide technique during 1 hour. The surface reactions were controlled 
with infrared spectroscopy. The amount of fluorescein bound to the surface of silica 
nanoparticles was determined spectrophotometrically at ǌ=490 nm. Fluorescein content 
within the samples of modified silica nanoparticles varied from 0.01 to 0.02 mmol/g. 
Another fluorescent dye that can be used for labeling of silica nanoparticles is considered to 
be indocyanine green. This fluorophore has an absorption band in the near-infrared region 
(ǌ=780 nm). We have developed the technique of indocyanine green immobilization on the 
surface of aminated silica. Then, fluorescently labeled silica nanoparticles were used for 
biodistribution studies. 
The above-described techniques of matrix synthesis of engrafted surface compounds can be 
easily applied for Aerosil modification. Combination of the molecular layering method with 
chemical assembly of engrafted organic compounds is especially promising for 
development of targeted nanopharmaceuticals. With use of this approach, thin layers of 
inorganic substances possessing magnetic properties can be laid on the Aerosil surface with 
subsequent modification of the latter by the organic compounds containing active centers 
crucial for immobilization of drug molecules. We believe that the use of chemically modified 
silica as a prototype carrier for targeted drug delivery holds great promise because of 
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several advantages, such as biocompatibility and biodegradation, low cost, and detailed 
account on the techniques of surface immobilization of drugs, fluorophores, and targeting 
ligands. 
5.2 Acute toxicity, biodistribution and biodegradation of silica nanoparticles  
To investigate the acute toxicity of silica nanoparticles experimentally, we studied the acute 
hemodynamic effects of nanoparticle formulations in the rat model. For this purpose, the 
suspensions of silica and fluorescein-doped silica nanoparticles in 0,9% sodium 
hydrochloride solution were prepared and administered intravenously 3 times with 20-
minute intervals between infusions. Control animals received vehicle. Measurements of 
heart rate, mean arterial pressure and pulse arterial pressure were done throughout the 
experiments. In all groups of animals, there were no significant alterations in heart rate over 
time. The first infusion of any tested nanoparticle formulation had no effect on 
hemodynamic parameters. Furthermore, there were no statistically significant differences in 
mean arterial pressure between the baseline time point and the end of the experiment. 
However, the second and the third infusions of silica nanoparticles evoked transient 
increases of mean arterial pressure. There were significant increases in pulse arterial 
pressure in the animals that received silica nanoparticles at the end of the observation. 
Administration of fluorescein-labeled silica nanoparticles resulted in increase of pulse 
arterial pressure too, while pulse arterial pressure in controls was unaffected throughout the 
entire experiment. Thus, intravenous infusion of silica nanoparticle formulations caused 
mild changes in systemic hemodynamic parameters which appears to be indicative of 
appropriate biocompatibility of these nanomaterials. 
Biodistribution of silica nanoparticles was studied with use of optical fluorescence. 
Fluorescein and indocyanine green were used for fluorescent labeling of silica nanoparticles. 
The animals received intravenous infusion of fluorescently labeled nanoparticles suspended 
in normal saline at a volume of 1 ml for 10 minutes. 20 minutes after the end of infusion, the 
animals were sacrificed by an overdose of anesthesia, and the following organs were 
removed for subsequent measurements: heart, brain, liver, spleen, lung, and kidney. Control 
animals were treated with the vehicle. The registration of fluorescence was performed using 
FLUM3 setup for fluorescent imaging of small animals and biopsy specimens consisting of 
the mercury lamp illuminator and TV camera 285. The fluorescence of fluorescein- and 
indocyanine green-labeled nanoparticles was elicited by the use of band-pass interference 
filters of 435 and 780 nm, respectively. The images obtained in the experiments with 
fluorescein-labeled nanoparticles were split into RBG channels. Channel G has been chosen 
as target channel. The relative change in the level of fluorescence (i. e., percent change from 
control, ΔG, %) has been calculated as follows: ΔG=(G2 – G1)/G1, where G1 is the level of 
(auto)fluorescence in controls, G2 – the level of fluorescence in animals treated with 
fluorescein-labeled silica nanoparticles. In the experiments with indocyanine green-labeled 
nanoparticles, black-and-white images were obtained, and the relative change in the level of 
fluorescence (i. e., percent change from control, ΔF, %) was calculated as described above. 
The biodistribution data are shown in the Table 1. It should be noted that exposure of organ 
samples to UV light (ǌ=435 nm) for detection of fluorescein-doped nanoparticles was 
associated with significant deal of auto fluorescence which may interfere with the desired 
signal. Despite that, we observed predominant accumulation of fluorescein-labeled 
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nanoparticles within the lung, spleen and liver, that is, in the organs of reticulo-endothelial 
system. The use of indocyanine green was helpful in avoiding the high level of auto 
fluorescence because this fluorophore is excited at ǌ=780 nm. Generally, we found the 
highest accumulation of indocyanine green-labeled nanoparticles within the liver and 
kidney. Therefore, we recommend the use of infrared fluorophores for fluorescent labeling 
of silica nanoparticles and investigation of their biodistribution. 
 
Organ 
ǌ=780 nm ǌ=435 nm 
Control, 
F1 
Indocyanine 
green-labeled 
nanoparticles, 
F2 
ΔF, % 
 
Control, 
G1 
Fluorescein-
labeled 
nanoparticles, 
G2 
Δ G,% 
Heart 12±0.5 22±0.4 81±3.9 90±13.2 106±7.0 18±9.3 
Brain 26±0.5 35±0.5 77±7.0 115±7.1 119±13.4 5±2.8 
Liver 14±0.6 1213±193.0 8311±1232.0 95±31.5 113±24.8 22±14.6 
Spleen 16±9.9 20±4.2 62±27.0 81±10.2 99±7.1 23±6.8 
Lung 29±5.7 127±24.8 357±123.0 88±6.0 113±2.1 30±11.4 
Kidney 16±5.7 164±21.2 1018±373.0 76±0.4 82±6.2 9±6.7 
Table 1. Distribution of indocyanine green- and fluorescein-labelled silica nanoparticles at 
the organ level of Wistar rats after 30 min of dose administration 
Silica nanoparticle biodegradation was studied both in vitro and in vivo. When designing the 
experiments, we speculated that silica nanoparticles are undergoing biodegradation due to 
gradual erosion of their surface resultant in the formation of water-soluble salts of silicic 
acid which are excreted from the organism by the kidney (Fig. 2).  
 
Fig. 2. Hypothetical mechanism of silica nanoparticle biodegradation 
The suspension of Aerosil A380 in Krebs-Henseleit buffer having electrolyte composition 
similar to that of blood plasma with final concentration of silica nanoparticles 2 mg/ml and 
pH=7,4 was used for investigation of biodegradation in vitro. The experiments were 
performed in the settings of continuous stirring in the polymer 100 ml glass. The 
temperature of the media was maintained at 37°C by means of water jacketing. The samples 
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were continuously gassed with carbogen (95% О2 and 5% СО2). Total incubation time was 
equal to 15 hours. The samples were taken each 5 hours and analyzed for silicate content 
spectrophotometrically after reaction with molybdenum blue. The concentration of silicate 
in samples increased logarithmically with time. With use of mathematical analysis, we 
derived the value which corresponds to 95% biodegradation of silica and equals to 41 day. 
These data fit well to the results of Finnie et al. (2009) who studied biodegradation of sol-gel 
mesoporous silica microparticles. It has been shown in this study that silica microparticles 
are rapidly degraded in physiological buffer. Besides, the authors demonstrated that the 
addition of plasma proteins to the buffer retarded biodegradation by 20-30%. It follows, 
therefore, that in vivo biodegradation might be slower than in the in vitro settings. 
In vivo biodegradation of silica nanoparticles was studied in the male Wistar rats weighting 
200-250 g. Silica nanoparticles were infused intravenously at a dose of 2 mg/ml and volume 
of 1 ml followed by sampling of the liver at 1 h, 10, 20, and 30 days after infusion. The 
controls were animals received intravenous infusion of 1 ml of vehicle. Liver samples were 
dried at 90°C during 24 h to obtain constant weight. The liver was chosen for sampling and 
analyses on the basis of biodistribution experiments which showed maximal accumulation 
of silica in this organ. Quantitative analysis of silicon content within the samples was 
performed with atomic absorption spectroscopy. The mineralizat obtained after drying was 
analyzed on the atomic absorption spectrometer with electrothermic atomization and 
Zeman correction. Silicon content within the mineralizat was recalculated for the dry sample 
weight and expressed in µg/g. Silicon content in the liver of the rats according to the results 
of atomic absorption spectroscopy is shown on the Fig. 3.  
 
Fig. 3. Biodegradation of silica nanoparticles in vivo: silicon content in the liver at different 
durations after infusion of nanoparticles 
Silicon content in the liver of healthy rats averaged 4.4±1.55 µg/g. At 1 hour after silica 
nanoparticles infusion silicon content was increased up to 282.3±62.65 µg/g. 10 and 20 days 
after silica nanoparticle infusion silicon content in the liver was significantly lower 
(81.5±9.25 and 30.2±7.48 µg/g, respectively). This dynamics of silica dissolution is consistent 
with the data obtained in the in vitro model. However, at 30 days after silica nanoparticle 
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administration we failed to see any additional decrease in silicon tissue content (31.5±11.87 
µg/g). This fact might be accounted for by the higher stability of the intracellular pool of 
silica nanoparticles, produced as a result of their phagocytosis by the Kupffer cells and, to a 
lesser extent, silica nanoparticle internalization into hepatocytes and other liver cells. It 
remains unclear, however, whether this increased silicon content in the liver cells affects 
liver function or not. 
5.3 Passive heart targeting with silica nanoparticles 
For investigation of passive heart-targeted drug delivery with silica nanoparticles, we first 
studied biodistribution of unmodified nanoparticles in the rats with regional myocardial 
ischemia-reperfusion. For this purpose, the animals were randomly allocated into one of 
three groups: 1) controls (these animals received intravenous infusion of saline), 2) silica 
nanoparticle-treated animals (2 mg/ml, 1 ml intravenously) with sham surgical procedure; 
3) silica nanoparticle-treated animals with myocardial ischemia-reperfusion. Regional 
myocardial ischemia was induced by 30-minute left coronary artery ligation followed by 60 
minutes of reperfusion. Silica nanoparticles were infused for 10 minutes starting 5 minutes 
prior to reperfusion (Fig. 4). The left ventricle of the heart and liver were sampled at the end 
of the experiments, rinsed and dried at 90°C during 24 h to obtain constant weight. Silicon 
content in the organ samples was done with atomic absorption spectroscopy as described 
above. 
 
Fig. 4. Biodistribution of non-modified silica nanoparticles in rat model of myocardial 
ischemia-reperfusion. SNP – silica nanoparticles, IR – ischemia-reperfusion 
In controls, silicon content was found to be significantly higher in myocardial tissue then in 
the liver (32±2.8 vs. 4±2.3 µg/g, respectively, p<0.05) (Fig. 4). Of note, physiological role of 
this fact is currently unknown. Silica nanoparticle administration to sham-operated rats 
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resulted in dramatic rise in liver silicon content as compared to controls (163±19.5 vs. 4±2.3 
µg/g, respectively, p<0.01), while myocardial silicon concentration remained unaffected 
(27±9.7 vs. 32±2.8, respectively, p>0.05). Administration of silica nanoparticles to the animals 
with cardiac ischemia-reperfusion was associated with significant increase in myocardial 
silicon content in comparison to sham-operated animals (125±28.2 vs. 32±2.8 µg/g, 
respectively, p<0.05). Thus, the first evidence that non-modified silica nanoparticles can 
accumulate within the anatomical area at risk after regional myocardial ischemia-
reperfusion was provided in this study.  
The next series of experiments was performed to study the hemodynamic effects of 
nanoparticle-bound and free adenosine. Adenosine adsorption on the surface of silica 
nanoparticles was achieved by mixing the suspension of silica nanoparticles in 0.9% sodium 
chloride and adenosine solution in the same vehicle. The samples thus prepared were 
subjected to 10-minute sonication and left at +4ºC overnight. Silica nanoparticle-bound 
adenosine was administered to the rats intravenously for 10 minutes at a dose of 300 
Ǎg/kg×min. Control animals received 10-minute intravenous infusion of adenosine at a 
dose of 300 Ǎg/kg×min. Mean blood pressure was registered before the beginning of drug 
infusion, at 5th and 10th minutes of infusion, and at 5th and 10th minutes of recovery. The data 
on blood pressure values are shown in Table 2. The extent of blood pressure decrease was 
significantly less marked when adenosine was immobilized on the surface of nanoparticles 
(Fig. 5). 
MBP, 
mmHg 
Baseline 
5 min 
infusion 
10 min 
infusion 
5 min 
recovery 
10 min 
recovery 
Free ADO 125±12 82±7 85±9 128±5 119±13 
ADO+SNP 131±8 108±14* 113±11* 134±12 130±10 
Table 2. Attenuation of adenosine-induced hypotension after its immobilization on the 
surface of silica nanoparticles. MBP – mean blood pressure, ADO – adenosine, SNP – silica 
nanoparticles. * - p<0.05 vs. free adenosine 
 
Fig. 5. Representative blood pressure recording showing different blood pressure response 
to free and silica nanoparticle-bound adenosine. Initial free adenosine infusion was followed 
by recovery period and infusion of silica-nanoparticle bound adenosine. After recovery, one 
more episode of adenosine infusion was performed. ADO – adenosine, SNP – silica 
nanoparticles 
The final series of experiments was focused on investigation of the effect of free adenosine 
and nanoparticle-bound adenosine on infarct size. Five minutes prior to the end of 30-minte 
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ischemia, animals received either 10-minute adenosine infusion at a dose of 300 Ǎg/kg×min 
or infusion of adenosine adsorbed on silica nanoparticles in the equivalent dose. Control 
animals were treated with vehicle. Myocardial area at risk and infarct size were determined 
after 90 minutes of reperfusion with use of Evans blue and triphenyltetrazolium chloride 
staining, respectively. There were no differences in risk area between groups (Fig. 6).  
 
Fig. 6. Increased infarct-limiting effect of adenosine after its immobilization on silica 
nanoparticles. ADO – adenosine, SNP – silica nanoparticles 
Adenosine infusion caused significant reduction in infarct size as compared to controls 
(29±6,2 vs. 63±7,3%, respectively, p<0.01). Administration of adenosine adsorbed on silica 
nanoparticles resulted in additional significant decrease in infarct size in comparison to free 
adenosine (18±4.2 vs. 29±6,2, respectively, p<0.05). 
In conclusion, adsorption of adenosine on silica nanoparticles results in its passive delivery 
to the ischemic area of the heart which, in turn, leads to more pronounced infarct size 
limitation and attenuation of hemodynamic side effect typical for the drug used. 
5.4 Candidate drugs for heart-targeted delivery 
Several groups of drugs with different mechanisms of action might potentially be targeted 
to the heart with nano-sized carriers (Table 3). One of the most efficient means of 
myocardial protection known to date is ischemic preconditioning, a phenomenon which 
describes dramatically increased heart tolerance to prolonged ischemia occurring after one 
or several brief episodes of ischemia-reperfusion (Galagudza et al., 2008). It is well 
established that preconditioning can elicit several cardioprotective effects including infarct-
limitation, reduction of ischemic and reperfusion arrhythmias, prevention of endothelial 
dysfunction and attenuation of stunning. The mechanisms of preconditioning include 
generation of chemical triggers during brief bouts of ischemia, their interaction with 
corresponding sarcolemmal G-protein-coupled receptors with subsequent activation of 
multiple intracellular kinases, and, eventually, engagement of putative mitochondrial 
effectors responsible for initiation of energy-sparing processes. It has been shown that such 
preconditioning triggers as adenosine, bradykinin, and opioid peptides are all able to mimic 
www.intechopen.com
 
Novel Strategies in Ischemic Heart Disease 268 
the preconditioning response when administered exogenously. However, their clinical use 
at doses required for preconditioning-like response is hampered by the high risk of 
dangerous side effects. For example, intravenous administration of adenosine is associated 
with arterial hypotension and bradycardia (Takahama et al., 2009), while administration of 
bradykinin might lead to hypotension and bronchial spasm (Homma & Irvin, 1999). It 
follows, therefore, that targeted delivery of preconditioning mimetics or synthetic agonists 
of G-protein-coupled receptors might contribute to improved safety and efficacy profile of 
these compounds, especially taking into account the encouraging results with heart-targeted 
delivery of adenosine (Takahama et al., 2009). 
 
Mechanism Drug/ligand 
Activation of G-protein-coupled receptors 
(preconditioning) 
Bradykinin, opioids, adenosine and 
synthetic ligands of corresponding 
receptors 
Activation of tyrosine kinase receptors 
(angiogenesis, cardiac myocyte proliferation?) 
Insulin, insulin-like growth factor-1, 
transforming growth factor-ǃ1, 
erythropoietin, vascular endothelial 
growth factor, etc. 
Inhibition of mitochondrial permeability 
transition pore opening (attenuation of 
reperfusion injury, antiapoptotic effect) 
Cyclosporine 
Activation of peroxisome proliferator-
activated receptors gamma (reduction of 
inflammation, improved endothelial function) 
Rosiglitazone, pioglitazone 
Opening of ATP-sensitive potassium channels 
(improved mitochondrial function) 
Nicorandil 
Nitric oxide signaling pathway 
(preconditioning, vasodilation) 
Nitric oxide donors, atorvastatin, 
atrial natriuretic peptide, etc. 
Table 3. Candidate drugs for ischemic heart targeting 
Another group of compounds demonstrating cardioprotective effects are growth factors 
which interact with tyrosine kinase receptors. Such molecules as insulin, insulin-like growth 
factor-1, transforming growth factor-ǃ1, erythropoietin, vascular endothelial growth factor, 
and fibroblast growth factor may not only induce cytoprotective effect when administered 
either prior or just after index ischemia, but also possess late cardioprotective effects due to 
stimulation of angiogenesis and attenuation of inflammation (Boucher et al., 2008; Ueda et 
al., 2010). Again, heart-targeted delivery of growth factors may result in better outcome 
because of local increase in the concentration and reduction of such side effects as 
hypotension and hypersensitivity reactions. 
One more key player in the mechanisms of ischemia-reperfusion myocardial injury is 
mitochondrial permeability transition pore (mPTP). mPTP represents multiprotein complex 
localized in the inner mitochondrial membrane which functions as voltage-dependent 
nonselective channel. The probability of mPTP opening is very low during in both normal 
and ischemic environment. However, at reperfusion mPTP becomes opened thus making 
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inner mitochondrial membrane permeable for water, ions, and molecules with molecular 
weight up to 1.5 kDa. Major stimuli for mPTP opening are increased calcium concentration, 
mitochondrial matrix pH>7.0, increased concentration of reactive oxygen species, and 
mitochondrial membrane depolarization (Di Lisa et al., 2011). mPTP opening results in 
immediate complete depolarization of mitochondrial membrane and, therefore, loss of 
electrochemical gradient. In this situation, ATP synthase starts to degrade ATP in a futile 
attempt to regenerate membrane potential. Besides, massive swelling of mitochondrial 
matrix may contribute to mechanical rupture of the organelles with resultant release of 
several pro-apoptotic molecules normally retained in the intermembrane space. It follows 
that mPTP opening at the early moments of reperfusion can lead to development of lethal 
reperfusion injury by means of both necrosis and apoptosis. mPTP inhibitors were shown to 
be cardioprotective in experimental and clinical settings. Intravenous administration of 
mPTP inhibitor cyclosporine to the patients with acute ST-elevation myocardial infarction 
just prior to percutaneous coronary intervention resulted in significant reduction in infarct 
size as compared to controls (Piot et al., 2008). Cyclosporine is commonly used for immune 
suppression, and its prolonged use is associated with several serious side effects including 
renal failure, hepatotoxicity, infection, and increased risk of tumor development. Thus, it is 
of prime importance to develop the technique of targeted delivery of cyclosporine to the 
ischemic heart which may help to attenuate its systemic toxicity. 
Peroxisome proliferator-activated receptors (PPAR) are nuclear receptors that function as 
transcription factors for numerous genes. In terms of myocardial ischemia-reperfusion 
injury, activation of PPARǄ with either endogenous ligands or thiazolidinedione derivatives 
has been shown to be cardioprotective (Di Paola & Cuzzocrea, 2007). Potential mechanisms 
of PPARǄ-mediated cardioprotection include inhibition of the activation of nuclear 
transcription factor ǋB, stimulation of endothelial NO-synthase function, and increased 
expression of heme oxygenase-1. Decreased function of nuclear transcription factor ǋB in the 
ischemic-reperfused heart is supposed to be beneficial since this transcription factor 
positively regulates a battery of proinflammatory genes, all of which contribute to 
secondary injury in the infarcted area.  
ATP-sensitive potassium channels have been believed to be major end effectors of ischemic 
preconditioning in the late 90s. There are two main populations of ATP-sensitive potassium 
channels, that is, sarcolemmal and mitochondrial. Currently, the cardioprotective role of 
sarcolemmal ATP-sensitive potassium channels has been unequivocally proved while there 
is some debate as to the role of mitochondrial channels (Hanley & Daut, 2005). Several ATP-
sensitive potassium channel openers were shown to exert preconditioning-like protective 
effect in the experimental models. However, the only drug from this group that is approved 
for use in humans is nicorandil. The results of IONA trial demonstrated reduced incidence 
of acute coronary syndrome in the patients with stable angina receiving nicorandil. It seems, 
therefore, that targeted delivery of nicorandil to the heart might further strengthen its 
cardioprotective effect. 
Finally, pharmacological modulation if nitric oxide (NO)-dependent pathway in the heart is 
also of interest. It has been shown that endogenous NO participation in the mechanisms of 
cardiac protection if unlikely but exogenous supplementation of the heart with NO can 
mimic the protective effect of preconditioning (Dawn & Bolli, 2002). NO-dependent 
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mechanisms were also proposed for infarct-limiting effect of atorvastatin (Atar et al., 2006) 
and atrial natriuretic peptide (Okawa et al., 2003). 
In conclusion, the list of cardioprotective drugs which might be delivered to the heart with 
nanocarriers is incomplete. By now, hundreds of drugs were shown to be cardioprotective 
in the preclinical models. However, very few of them were proved to be effective in the 
patients with coronary artery disease. The reasons for this failure are multiple and analyzed 
elsewhere, but at least one is the fact that many drugs have significant side effects which 
hinder the process of clinical translation. Recent evidence indicates that some side effects 
can be substantially reduced when the drug is navigated to the tissue of interest by the 
nanocarrier. Targeted delivery concept holds promise for development of new efficient and 
safe therapies for ischemic heart disease. 
6. Perspectives and future work 
Although the concept of targeted drug delivery to the ischemic heart seems to be generally 
coherent, it is evident that large questions lie ahead. Systemic administration of 
multifunctional drug carriers results in their selective accumulation in the target tissues with 
normal blood flow. It might be problematic to achieve the minimal effective dose of the 
nanopharmaceutical within the tissue subjected to critical ischemia. This problem may be 
solved by the increased residence time of nanocarriers within the adjacent to ischemic 
tissues providing diffusion of the drug into the poorly vascularized area. Alternative 
solution may involve increased loading of the nanoparticles with payload and/or targeting 
ligands. On the other hand, intensive functionalization of nanoparticles may result in better 
recognition by the immune system and faster clearance by the reticulo-endothelial system.  
Insufficient evidence is currently available on the clinical effectiveness of nanoparticulate 
drug carriers. Additional studies are required to elucidate the pharmacokinetics of 
nanocarriers as well as their biodistribution and putative toxicity. All newly developed 
nanosystems for targeted delivery possess unique properties requiring individual testing. 
The refinement of the techniques of nanocarrier fabrication is aimed at ensuring of better 
uptake of nanoparticles by the target cells, formation of higher gradient of drug between 
injured and intact tissue, and more complete avoidance of drug toxicity. The 
accomplishment of these goals will be a major step in development of an ideal tool for 
targeted delivery of the drug into the tissue of interest. 
7. Conclusion 
Concepts of passive and active targeting can be applied to the development of targeted drug 
delivery to the ischemic myocardial tissue. Targeted delivery of various cardioprotective 
agents to the ischemic cardiac muscle with use of nanoparticles seems to be a challenging 
approach to treatment of coronary artery disease.  
Silica nanoparticles are non-toxic materials that might be potentially used as carriers for 
heart-targeted drug delivery. Silica nanoparticles can be functionalized with use of the 
techniques of immobilization and chemical assembly. Immobilization of adenosine on the 
surface of silica nanoparticles resulted in enhancement of free adenosine-mediated infarct 
size limitation in the animal model. Furthermore, hypotensive effect of adenosine was 
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attenuated after its adsorption on silica nanoparticles. Additional studies will be required to 
demonstrate silica nanoparticle biocompatibility in the chronic experiments.  
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